-
Company management and clinical trial investigators will review
interim results on the long-term safety and efficacy data of
inclisiran from ongoing ORION-3 study
PARSIPPANY, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MDCO&src=ctag" target="_blank"gt;$MDCOlt;/agt;–The Medicines Company (NASDAQ:MDCO) will host a conference call and
webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT.
During the call, the Company’s management and clinical trial
investigators will review interim results on the long-term safety and
efficacy data of inclisiran from the ongoing ORION-3 study. The data
will be presented during the late-breaking clinical trial session
earlier the same day at the National Lipid Association (NLA) 2019
Scientific Sessions in Miami.
Inclisiran, the first cholesterol-lowering therapy in the small
interfering RNA (siRNA) class, is the only medicine in late-stage
clinical development with the potential to deliver potent, durable and
consistent lowering of LDL cholesterol through twice-a-year dosing.
ORION-3 is an open-label Phase 2, extension study (of ORION-1) to assess
the efficacy, safety and tolerability of long-term dosing of inclisiran.
The study also evaluates safety and efficacy of switching patients
treated with evolocumab to inclisiran. Follow up for this latter group
is still ongoing and will be presented at a later date.
Conference Call
The conference call may be accessed as follows:
U.S./Canada: (877) 407-0312
International: (201) 389-0899
Conference ID: 13690839
The slide deck and live webcast may be accessed in the Investors
section of The Medicines Company website.
A taped replay of the conference call will be available for
approximately one month. The replay may be accessed as follows:
U.S./Canada: (877) 660-6853
International: (201) 612-7415
Conference ID: 13690839
A replay of the webcast will also be available in the Investors
section of The Medicines Company website.
About The Medicines Company
The Medicines Company is a biopharmaceutical company whose purpose is to
halt the deadly progression of atherosclerosis and the cardiovascular
risk created by high levels of LDL-C, or bad cholesterol. Our team is
focused on transformational solutions that address the daily challenges
that patients, physicians and payers confront in cardiovascular care.
The Company is headquartered in Parsippany, New Jersey. For more
information, please visit www.themedicinescompany.com
and follow us on Twitter @MDCONews
and LinkedIn.
About Inclisiran
Inclisiran is a small interfering RNA (siRNA) therapy being studied to
evaluate its ability to lower low-density lipoprotein (LDL) cholesterol
– also known as LDL-C or bad cholesterol. Inclisiran is designed to
prevent the production of proprotein convertase subtilisin/kexin type 9
(PCSK9) at its source in the liver. Inclisiran is not yet approved for
use by the FDA or any other regulatory authority. The Medicines Company
obtained global rights to develop, manufacture and commercialize
inclisiran under a license and collaboration agreement with Alnylam
Pharmaceuticals.
Contacts
Investor Relations
Krishna Gorti, M.D.
Vice President,
Investor Relations
973 290 6122
krishna.gorti@themedco.com
Media Inquiries
Michael Blash
Vice President,
Communications
973 290 6100
michael.blash@themedco.com